At the Cantor Global Healthcare Conference, Novo Nordisk’s senior vice president of finance and operations, Ulrich Otte, said, “It is very likely that Ozempic will be part of negotiations in the coming round, and we’re ready for that.” The executive was referring to bargaining with the U.S. government over the weight loss drug’s price.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Novo Nordisk Advances Share Buyback Program
- Korro Bio announces collaboration with Novo Nordisk
- Roche obesity pill tied to high rates of nausea in ST study, Bloomberg says
- Novo amycretin safety ‘not quite as clean as we’d like,’ says Deutsche Bank
- Novo obesity data validate Viking’s approach, says William Blair